Treatment of chronic hepatitis C virus infection in the HIV-infected patient
- Jürgen Kurt Rockstroh, MD
Jürgen Kurt Rockstroh, MD
- Professor of Medicine
- Department of Medicine I, University of Bonn, Germany
The consequences of hepatitis C virus (HCV) infection in HIV-infected patients are significant and include accelerated liver disease progression, high rates of end-stage liver disease, and shortened lifespan after hepatic decompensation, in particular among those with more advanced immunodeficiency [1-3]. In the era of potent antiretroviral therapy, end-stage liver disease remains a major cause of death among HIV-infected patients who are coinfected with HCV [4,5].
This topic will address the management of the HIV/HCV-coinfected patient. The epidemiology, natural history, diagnosis, and evaluation of this patient population are discussed elsewhere. (See "Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient" and "Evaluation of the HIV-infected patient with chronic hepatitis C virus infection".)
Discussion of acute HCV infection is found elsewhere. (See "Clinical manifestations, diagnosis, and treatment of acute hepatitis C virus infection in adults".)
Guidelines for the diagnosis and management of HCV infection produced jointly by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) are updated on an ongoing basis and can be accessed at www.hcvguidelines.org . Management of coinfection is addressed in the US Department of Health and Human Services guidelines for the use of antiretroviral agents in adults and adolescents . In addition, the European Association for the Study of the Liver (EASL) HCV guidelines were updated in 2016 , and the coinfection guidelines of the European Clinical AIDS Society were updated in 2016 [9,10]. The discussion in this topic is generally consistent with these guidelines.
GOALS OF THERAPY
The objective of HCV antiviral treatment is to cure HCV infection, as reflected by a sustained virologic response, which is associated with substantial reductions in liver-related morbidity and mortality.
- Kirk GD, Mehta SH, Astemborski J, et al. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med 2013; 158:658.
- Goedert JJ, Eyster ME, Lederman MM, et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 2002; 100:1584.
- Vogel M, Page E, Boesecke C, et al. Liver fibrosis progression after acute hepatitis C virus infection in HIV-positive individuals. Clin Infect Dis 2012; 54:556.
- Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632.
- Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 2014; 384:241.
- Recommendations for Testing, Managing, and Treating Hepatitis C. Joint panel from the American Association of the Study of Liver Diseases and the Infectious Diseases Society of America. http://www.hcvguidelines.org/ (Accessed on August 01, 2016).
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (Accessed on April 08, 2015).
- European Association for the Study of the Liver Recommendations on Treatment of Hepatitis C 2016. www.easl.eu/medias/cpg/HCV2016/Summary.pdf (Accessed on February 21, 2017).
- Eurpean AIDS Clinical Society Guidelines. Version 8.1, October 2016. www.eacsociety.org/files/guidelines_8.1-english.pdf (Accessed on February 21, 2017).
- Ryom L, Boesecke C, Gisler V, et al. Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV-positive persons. HIV Med 2016; 17:83.
- Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010; 51:1122.
- Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139:1593.
- Soriano V, Labarga P, Ruiz-Sancho A, et al. Regression of liver fibrosis in hepatitis C virus/HIV-co-infected patients after treatment with pegylated interferon plus ribavirin. AIDS 2006; 20:2225.
- Berenguer J, Alvarez-Pellicer J, Martín PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50:407.
- Cooper CL. De-"Liver"-ing HIV/hepatitis C virus-coinfected patients from antiretroviral hepatotoxicity. J Infect Dis 2007; 196:656.
- Mira JA, Rivero-Juárez A, López-Cortés LF, et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis 2013; 56:1646.
- Berenguer J, Zamora FX, Carrero A, et al. Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis. J Acquir Immune Defic Syndr 2014; 66:280.
- Hepatitis C Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Is response to anti-hepatitis C virus treatment predictive of mortality in hepatitis C virus/HIV-positive patients? AIDS 2017; 31:661.
- Labarga P, Soriano V, Vispo ME, et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007; 196:670.
- Balagopal A, Kandathil AJ, Higgins YH, et al. Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus/hepatitis C virus coinfected patients. Hepatology 2014; 60:477.
- Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014; 312:353.
- Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA 2015; 313:1232.
- Basu P, Shah N, Aloysius M. Simeprevir and sofosbuvir with modified doses of ribavirin therapy on telaprevir-experience coinfeced (with HIV) cirrhotics with chronic hepatitis C: A randomized open label clinical pilot study: STOP C. Presented at the American Association for the Study of Liver Diseases Liver Meeting, Boston MA, November 7-11, 2014. Abstract #993.
- Rockstroh JK, Puoti M, Rodriguez-Torres M, et al. Sofosbuvir and ribavirin therapy for the treatment of HIV/HCV coinfected patients with HCV GT1-4 infection: The PHOTON-1 and 2 trials. Presented at the American Association for the Study of Liver Diseases Liver Meeting, Boston MA, November 7-11, 2014. Abstract #195.
- Naggie S, Cooper C, Saag M, et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med 2015; 373:705.
- Ingiliz P, Christensen S, Kimhofer T, et al. Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01). Clin Infect Dis 2016; 63:1320.
- Brau N, Wyles D, Kottilil S, et al. Sofosbuvir/velpatasvir for 12 weeks in patients coinfected with HCV and HIV-1: The ASTRAL-5 study. Presented at the 21st International AIDS Conference, Durban South Africa, July 19-22, 2016.
- Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015; 385:1087.
- Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV 2015; 2:e319.
- Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 2015; 313:1223.
- Rockstroh JK, Orkin C, Viani RM, et al. TURQUOISE-I Part 2: Safety and efficacy of ombitasvir/paritaprevir/ritonavir +/- dasabuvir with or without ribavirin in patients with HIV-1 and HCV GT1 or GT4 co-infection. Presented at the 21st International AIDS Conference. Durban, July 18-22, 2016. Abstract #WEAB0304.
- Andreoni M, Teti E, Antinori A, et al. Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients With HIV/HCV Coinfection: Results of an Italian Compassionate Use Program. Clin Infect Dis 2017.
- del Bello D, Bichoupan K, Levine C, et al. Real-world data on HIV-positive patients with HCV treatment with sofosbuvir and/or simeprevir. Presented at the 22st Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 23-26, 2015. Abstract # 647.
- Gilmore J, Lynn K, Breen D, et al. Effectiveness of sofosbuvir/simeprevir for HIV/HCV patients in clinical practice. Presented at the 22st Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 23-26, 2015.
- Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med 2015; 373:714.
- Mandorfer M, Schwabl P, Steiner S, et al. Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease. AIDS 2016; 30:1039.
- Christensen S, Ingiliz P, Hueppe D, et al. German cohort on sofosbuvir based therapy for HCV/HIV- and HCV-infection (GESOCO). Presented at the 22st Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 23-26, 2015. Abstract #646.
- Molina JM, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet 2015; 385:1098.
- Rockstroh JK, Welzel TM, Ingiliz P, et al. Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV in patients coinfected with HIV: Interim results of a multicenter compassionate use program. Presented at the American Association for the Study of Liver Diseases Liver Meeting, San Francisco CA, November 13-17, 2015. Abstract #1058.
- Wyles D, Brau N, Kottilil S, et al. Sofosbuvir/velpatasvir for 12 weeks in patients coinfected with HCV and HIV-1: The ASTRAL-5 study. Presented at the 51st Annual Meeting of the European Association for the Study of the Liver (EASL), Barcelona, Spain, April 13-17, 2016.
- Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61:1127.
- Rockstroh J, Welzel TM, Ingiliz P, et al. Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV in patients coinfected with HIV: Interim results of a multicenter European compassionate use program. AASLD 2015.
- Naggie S, Cooper C, Saag M, et al. Ledipasvir/sofosbuvir for 12 weeks in patients coinfected with HCV and HIV-1. Presented at the 22st Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 23-26, 2015. Abstract #152LB
- Rodríguez-Nóvoa S, Morello J, González M, et al. Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin. AIDS 2008; 22:2535.
- Balzarini J, Lee CK, Herdewijn P, De Clercq E. Mechanism of the potentiating effect of ribavirin on the activity of 2',3'-dideoxyinosine against human immunodeficiency virus. J Biol Chem 1991; 266:21509.
- Mauss S. Treatment of viral hepatitis in HIV-coinfected patients-adverse events and their management. J Hepatol 2006; 44:S114.
- McGovern B, Bica I. Risk of HAART therapy in hepatitis C. Hepatology 2002; 35:730.
- Harvoni (ledipasvir-sofosbuvir). US FDA approved product information. National Library of Medicine.
- German P, Pang PS, Fang L, et al. Drug-drug interaction profile of the fixed-dose combination tablet ledipasvir/sofosbuvir. Presented at the American Association for the Study of Liver Diseases Liver Meeting, Boston MA, November 7-11, 2014. Abstract #1976.
- MacBrayne C, Fierer DS, Marks KM, et al. Ledipasvir/sofosbuvir raises tenofovir diphosphate concentrations in red cells. Presented at the Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 13-16, 2017, Abstract #404.
- Garrison K, Custodio J, Pang P, et al. Drug interactions between anti-HCV antivirals ledipasvir/sofosbuvir and integrase strand transfer inhibitor-based regimens. Presented at the 16th International Workshop on Clinical Pharmacology of HIV. Washington, DC. May 26, 2015, Abstract #71.
- Custodio J, et al. Tenofovir (TFV) exposures: Coadministration of LDV/SOF with E/C/F/TAF or R/F/TAF vs other ARVs. Presented at IDWeek, San Diego, CA, October 7 - 11, 2015. Abstract #727.
- VIEKIRA PAK (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets). US FDA approved product information. National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on January 01, 2015).
- Khatri A, Dutta S, Wang H, et al. Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors. Clin Infect Dis 2016; 62:972.
- Wyles D, Saag M, Viani RM, et al. TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir. J Infect Dis 2017; 215:599.
- Khatri A, Wang W, Podsadecki T, et al. Drug-drug interactions of the direct acting antiviral regimen of ABT-450/r, ombitasvir and dasabuvir with emtricitabine+tenofovir, raltegravir, rilpivirine and efavirenz. Presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 5-9, 2014; Washington, DC.
- Dieterich D, Rockstroh JK, Orkin C, et al. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study. Clin Infect Dis 2014; 59:1579.
- Fleming CA, Craven DE, Thornton D, et al. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003; 36:97.
- Mehta SH, Lucas GM, Mirel LB, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 2006; 20:2361.
- Butt AA, Khan UA, Shaikh OS, et al. Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers. HIV Clin Trials 2009; 10:25.
- Taylor LE, Schwartzapfel B, Allen S, et al. Extending treatment for HCV infection to HIV-HCV coinfected individuals with psychiatric illness and drug dependence. Clin Infect Dis 2003; 36:1501.
- GOALS OF THERAPY
- Sustained virologic response as cure
- Clinical benefits of cure
- EFFECT OF HIV INFECTION ON RESPONSE TO HCV TREATMENT
- PATIENT EVALUATION
- Evaluation to guide management decisions
- Deciding when to treat
- ANTIRETROVIRAL MANAGEMENT
- ART-naïve patients
- - Selection of ART regimen
- - Timing of ART initiation
- ART-experienced patients
- HCV REGIMEN SELECTION
- Regimen options by genotype
- - Genotype 1 infection
- - Genotype 2 infection
- - Genotype 3 infection
- - Genotypes 4, 5, and 6 infection
- Potential drug interactions with ART
- - Ribavirin
- - Sofosbuvir
- - Ledipasvir-sofosbuvir
- - Sofosbuvir-velpatasvir
- - Elbasvir-grazoprevir
- - Ombitasvir-paritaprevir-ritonavir plus dasabuvir
- - Daclatasvir
- - Simeprevir
- PATIENT MONITORING
- BARRIERS TO CARE
- INFORMATION FOR PATIENTS
- SUMMARY AND RECOMMENDATIONS